Amphastar Pharmaceuticals (AMPH) Income towards Parent Company: 2013-2025
Historic Income towards Parent Company for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $17.4 million.
- Amphastar Pharmaceuticals' Income towards Parent Company fell 57.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year decrease of 35.76%. This contributed to the annual value of $148.4 million for FY2024, which is 8.91% up from last year.
- According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Income towards Parent Company is $17.4 million, which was down 44.09% from $31.0 million recorded in Q2 2025.
- Over the past 5 years, Amphastar Pharmaceuticals' Income towards Parent Company peaked at $49.6 million during Q3 2023, and registered a low of $4.0 million during Q1 2021.
- In the last 3 years, Amphastar Pharmaceuticals' Income towards Parent Company had a median value of $31.0 million in 2025 and averaged $32.6 million.
- As far as peak fluctuations go, Amphastar Pharmaceuticals' Income towards Parent Company spiked by 703.36% in 2021, and later slumped by 57.09% in 2025.
- Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Income towards Parent Company stood at $20.0 million in 2021, then soared by 46.51% to $29.3 million in 2022, then rose by 14.09% to $33.4 million in 2023, then declined by 21.40% to $26.2 million in 2024, then crashed by 57.09% to $17.4 million in 2025.
- Its Income towards Parent Company stands at $17.4 million for Q3 2025, versus $31.0 million for Q2 2025 and $25.3 million for Q1 2025.